These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103 [TBL] [Abstract][Full Text] [Related]
4. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators N Engl J Med; 1998 May; 338(21):1498-505. PubMed ID: 9599104 [TBL] [Abstract][Full Text] [Related]
5. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction. Okmen E; Cakmak M; Tartan Z; Cam N Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426 [TBL] [Abstract][Full Text] [Related]
6. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E; N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424 [TBL] [Abstract][Full Text] [Related]
7. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). Huynh T; Theroux P; Snapinn S; Wan Y; Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321 [TBL] [Abstract][Full Text] [Related]
9. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators. Zhao XQ; Théroux P; Snapinn SM; Sax FL Circulation; 1999 Oct; 100(15):1609-15. PubMed ID: 10517731 [TBL] [Abstract][Full Text] [Related]
10. The glycoprotein IIb/IIIa platelet receptor blocker tirofiban, but not heparin, counteracts platelet aggregation in unstable angina pectoris. Mattsson E; Martinsson A; Nyqvist O; Rasmanis G; Sylvén C; Karlberg KE Am J Cardiol; 1997 Oct; 80(7):938-40. PubMed ID: 9382012 [TBL] [Abstract][Full Text] [Related]
11. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes. Campbell P N Engl J Med; 2001 Nov; 345(21):1573-4; author reply 1574-5. PubMed ID: 11794228 [No Abstract] [Full Text] [Related]
12. Efficacy of low-molecular-weight heparin in acute coronary syndromes. Wallentin L Am Heart J; 2000 Feb; 139(2 Pt 2):S29-32. PubMed ID: 10650313 [No Abstract] [Full Text] [Related]
13. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation; 1998 Jun; 97(24):2386-95. PubMed ID: 9641689 [TBL] [Abstract][Full Text] [Related]
14. Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention. Ronner E; Dykun Y; van den Brand MJ; van der Wieken LR; Simoons ML Eur Heart J; 1998 Nov; 19(11):1608-16. PubMed ID: 9857912 [No Abstract] [Full Text] [Related]
15. [Acute coronary syndromes: an update. I. Pathogenesis and drug therapy]. Auer J; Berent R; Maurer E; Mayr H; Weber T; Eber B Herz; 2001 Mar; 26(2):99-110. PubMed ID: 11349620 [TBL] [Abstract][Full Text] [Related]
16. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Cohen M; Théroux P; Weber S; Laramée P; Huynh T; Borzak S; Diodati JG; Squire IB; Deckelbaum LI; Thornton AR; Harris KE; Sax FL; Lo MW; White HD Int J Cardiol; 1999 Dec; 71(3):273-81. PubMed ID: 10636535 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. Blazing MA; de Lemos JA; White HD; Fox KA; Verheugt FW; Ardissino D; DiBattiste PM; Palmisano J; Bilheimer DW; Snapinn SM; Ramsey KE; Gardner LH; Hasselblad V; Pfeffer MA; Lewis EF; Braunwald E; Califf RM; JAMA; 2004 Jul; 292(1):55-64. PubMed ID: 15238591 [TBL] [Abstract][Full Text] [Related]
18. Use of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Fernandez JS; Sadaniantz A Med Health R I; 2001 Feb; 84(2):37-43. PubMed ID: 11272658 [No Abstract] [Full Text] [Related]
19. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Théroux P; Alexander J; Pharand C; Barr E; Snapinn S; Ghannam AF; Sax FL Circulation; 2000 Nov; 102(20):2466-72. PubMed ID: 11076818 [TBL] [Abstract][Full Text] [Related]
20. Role of tirofiban in the medical treatment of the intermediate-risk patient with an acute coronary syndrome cannot be denied. Goldberg L; Mekel J Am J Cardiol; 2000 Dec; 86(12):1401-2. PubMed ID: 11192745 [No Abstract] [Full Text] [Related] [Next] [New Search]